Evidence map›Paper›PMID 29606501›Full record

ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2018

CRISPR Gene Editing in the Kidney.

Nelly M Cruz, Benjamin S Freedman

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Immune Landscape in Kidney Transplantation.Journal of inflammation research · 2025
    Review
  13. RNA-Based Therapies in Kidney Diseases.Journal of inflammation research · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Genome editing and kidney health.Clinical kidney journal · 2024
    Review
  18. Review
  19. Article
  20. CRISPR-Cas9-Mediated Correction ofInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nelly M CruzDivision of Nephrology, University of Washington School of Medicine, Seattle WA; Kidney Research Institute, University of Washington School of Medicine, Seattle WA; Institute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, Seattle WA; Department of Medicine, University of Washington School of Medicine, Seattle WA.
Benjamin S FreedmanDivision of Nephrology, University of Washington School of Medicine, Seattle WA; Kidney Research Institute, University of Washington School of Medicine, Seattle WA; Institute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, Seattle WA; Department of Medicine, University of Washington School of Medicine, Seattle WA. Electronic address: benof@uw.edu.
University of Washington · US

Funding

Modeling Polycystic Kidney Disease Using Human Induced Pluripotent Stem CellsK01DK102826 · NIDDK · UNIVERSITY OF WASHINGTON · PI FREEDMAN, BENJAMIN SOLOMON · 2014 to 2018
$743k
NIDDK NIH HHS K01 DK102826
6 · The paper itself

Abstract

CRISPR is a nuclease guidance system that enables rapid and efficient gene editing of specific DNA sequences within genomes. We review applications of CRISPR for the study and treatment of kidney disease. CRISPR enables functional experiments in cell lines and model organisms to validate candidate genes arising from genetic studies. CRISPR has furthermore been used to establish the first models of genetic disease in human kidney organoids derived from pluripotent stem cells. These gene-edited organoids are providing new insight into the cellular mechanisms of polycystic kidney disease and nephrotic syndrome. CRISPR-engineered cell therapies are currently in clinical trials for cancers and immunologic syndromes, an approach that may be applicable to inflammatory conditions such as lupus nephritis. Use of CRISPR in large domestic species such as pigs raises the possibility of farming kidneys for transplantation to alleviate the shortage of donor organs. However, significant challenges remain, including how to effectively deliver CRISPR to kidneys and how to control gene editing events within the genome. Thorough testing of CRISPR in preclinical models will be critical to the safe and efficacious translation of this powerful young technology into therapies.

Indexed as

AnimalsClustered Regularly Interspaced Short Palindromic RepeatsFemaleForecastingGene EditingGene Expression RegulationGenetic TherapyHumansKidney DiseasesKidney TransplantationMalePluripotent Stem CellsRisk AssessmentTreatment Outcomeanimal modelchimeric antigen receptor T-cells (CAR-T)CRISPRgene editinggene knockoutgene therapygenomehuman pluripotent stem cells (hPSC)in vitro culturenephrotic syndromeorganoidspolycystic kidney disease (PKD)review

Identifiers

PMID29606501
PMCPMC6029248
OpenAlexW2794543671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.